dc.contributor.author | Wilens, Timothy Edwin | |
dc.contributor.author | Klint, Thorsten | |
dc.contributor.author | Adler, Lenard | |
dc.contributor.author | West, Scott | |
dc.contributor.author | Wesnes, Keith | |
dc.contributor.author | Graff, Ole | |
dc.contributor.author | Mikkelsen, Birgit | |
dc.date.accessioned | 2011-04-08T16:30:39Z | |
dc.date.issued | 2008 | |
dc.identifier.citation | Wilens, Timothy E., Thorsten Klint, Lenard Adler, Scott West, Keith Wesnes, Ole Graff, and Birgit Mikkelsen. 2008. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions : BBF 4: 24. | en_US |
dc.identifier.issn | 1744-9081 | en_US |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:4817628 | |
dc.description.abstract | Background: NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD. Methods: The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18–55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks. Multiple assessments including computerized neuropsychological evaluation were performed. Results: There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p less than 0.45). However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p less than 0.01). For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo. NS2359 improved composite factor scores of attention, episodic- and working memory. No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects. Conclusion: No overall effect of NS2359 was found on overall symptoms of ADHD. There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BioMed Central | en_US |
dc.relation.isversionof | doi:10.1186/1744-9081-4-24 | en_US |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442604/pdf/ | en_US |
dash.license | LAA | |
dc.title | A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD | en_US |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en_US |
dc.relation.journal | Behavioral and Brain Functions : BBF | en_US |
dash.depositing.author | Wilens, Timothy Edwin | |
dc.date.available | 2011-04-08T16:30:39Z | |
dash.affiliation.other | HMS^Psychiatry-Massachusetts General Hospital | en_US |
dc.identifier.doi | 10.1186/1744-9081-4-24 | * |
dash.contributor.affiliated | Wilens, Timothy | |